|Brand name(s), other common name(s)||Vidaza®|
|Drug type||Hypomethylating (Demethylating) agent|
|How the drug is given||Subcutaneous (SC) injection or intravenously (IV)|
Azacitidine is FDA approved to treat people who have certain myelodysplastic syndrome subtypes and chronic myelomonocytic leukemia.
Side effects needing medical attention:Black, tarry stools; bladder pain; bleeding gums; blood in urine or stool; cloudy urine; body aches or pain; burning or stinging of skin; chest pain or tightness in the chest; chills; ear, nose or chest congestion; cough; diarrhea; difficulty breathing, shortness of breath or wheezing; difficulty swallowing; dizziness; fast heartbeat; fever; frequent urge to urinate; headache; hives; hoarseness; itching; loss of voice or voice changes; lower back or side pain; muscle aches; nausea or vomiting; pain or tenderness around eyes and cheekbones; painful cold sores or blisters on lips, nose, eyes or genitals; painful or difficult urination; pain, redness, swelling, tenderness or warmth on skin; pale skin; pinhead-sized red spots on skin; puffiness or swelling of the eyelids or around the eyes, face, lips or tongue; rapid heartbeat; sore throat; sores, ulcers, or white spots on lips or in mouth; swollen glands; tender, swollen glands in neck; troubled breathing with exertion; unusual bleeding or bruising; unusual tiredness or weakness.